Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis
Open Access
- 29 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12), e29492
- https://doi.org/10.1371/journal.pone.0029492
Abstract
Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels serve as a biomarker of disease severity in patients with early arthritis (EA). Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (β Coefficient [95% confidence interval]: 0.12 [0.06–0.18]; p<0.001) or ACPA (0.34 [0.01–0.67]; p = 0.044) were significantly and independently associated with a higher DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence interval 1.18–2.7; p = 0.007). Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment.Keywords
This publication has 41 references indexed in Scilit:
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature searchAnnals Of The Rheumatic Diseases, 2010
- A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone massArthritis Research & Therapy, 2010
- Does gene expression analysis inform us in rheumatoid arthritis?Annals Of The Rheumatic Diseases, 2009
- Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathwayAnnals Of The Rheumatic Diseases, 2008
- Biologic therapy for early rheumatoid arthritis: the latest evidenceCurrent Opinion in Rheumatology, 2008
- The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?Arthritis Research & Therapy, 2008
- Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin‐15 on the cell surface and promote osteoclastogenesis in autologous monocytesArthritis & Rheumatism, 2006
- The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: New insights from animal modelsArthritis & Rheumatism, 2005
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988